Skip to main content

Table 1 Clinical Characteristics of Mongolia and Thailand Cohorts IQR: Interquartile range; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDV: Hepatitis D virus. AFP: alpha-fetoprotein level. AAV2/13 refers to any sequence that most closely resembles the full AAV2 genome or the partial AAV13 genome but could be phylogenetically in between. Missing data excluded. Entries with a – were not measured

From: Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis

  Mongolia   Thailand (HCC)   Thailand (iCCA)  
  N or mean % N or mean % N or mean %
Age (median, IQR) 60 55–66 56.3 51–61 59.5 54–65
BMI (median, IQR) 24.7 21.3–27.9 22.8 20.8–25.3 22.3 19.8–24.4
Smoker 19/62 30.6 % 30/45 66.7 % 55/100 55 %
Drink Alcohol 8/62 12.9 % 37/47 78.7 % 64/100 64 %
HBV (HBsAg) 48/70 68.6 % 22/42 52.4 % 2/84 2.4 %
HCV (HCAb) 40/70 57.1 % 5/40 12.5 % 3/83 3.6 %
HDV (HDAb) 27/70 38.6 % - - - -
Fam History Liver Cancer 11/61 18.0 % 18/59 30.5 % 41/94 43.6 %
Cirrhosis 27/56 48.2 % 23/36 63.8 % - -
AFP (median, IQR) - - 38.6 5.8-320.7 - -
Multinodular 13/61 21.3 % 12/36 33.3 % 3/42 7.1 %
TNM staging       
Stage I 1 1.9 % 13 36.1 % 16 40 %
Stage II 19 35.8 % 15 41.7 % 5 12.5 %
Stage III 31 58.5 % 5 13.9 % 7 17.5 %
Stage IV 2 3.8 % 3 8.3 % 12 30 %
AAV2/13 + Tumor RNA-Seq 0 0 % 0 0 % 0 0 %
AAV2/13 + Non-tumor RNA-Seq 2 2.9 % 3 6.4 % 14 14 %
AAV2/13 + Tumor Viral Capture DNA-Seq 0 0 % 1 33.3 % 4 4 %
AAV2/13 + Non-tumor Viral Capture DNA-Seq 0 0 % 3 6.4 % 13 13 %
AAV2/13 + Tumor Genome Insertion 0 0 % 1 2.1 % 2 2 %
AAV2/13 + Non-tumor Genome Insertion 0 0 % 2 4.3 % 9 9 %
AAV2/13 + Shared Genome Insertion 0 0 % 1 2.1 % 0 0 %